PTPRC and cancer: Levels of PD-L1 in non-immune cells (CD45− cells, mostly tumor cells) were found to be significantly higher in the low-dose group compared with the PBS group (Figure 9), which is consistent with our previous findings that cancer cells upregulate PD-L1 expression in response to CF33 virus.16